(XELOX) capecitabine plus oxaliplatin: Clinical efficacy and safety in the first-line treatment for metastatic gastric cancer

被引：0
|
作者：
Manuguerra, G. [1 ]
Alu, M. [1 ]
Leonardi, V. [1 ]
Laudani, A. [1 ]
Palmisano, V. [1 ]
Pepe, A. [1 ]
Arcuri, C. [1 ]
Savio, G. [1 ]
Cusimano, M. [1 ]
Calabria, C. [1 ]
Porretto, C. [1 ]
de Bella, M. Tamburo [1 ]
Agostara, B. [1 ]
机构：
[1] P O M Ascoli ARNAS Civico, Dipartimento Oncol, Div Med Oncol, Palermo, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [31] CAPECITABINE AND OXALIPLATIN (XELOX) COMBINATION CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER-A PHASE II STUDY
    Tawfik, Hesham
    El-Deen, Hanan Gamal
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 98
  • [32] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    M. Ozcelik
    H. Odabas
    O. Ercelep
    S. Yuksel
    A. G. Mert
    D. Aydin
    H. Surmeli
    D. Isik
    S. Isik
    A. Oyman
    B. B. Oven Ustaalioglu
    M. Aliustaoglu
    M. Gumus
    Clinical and Translational Oncology, 2016, 18 : 617 - 624
  • [33] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
    Sledge, G.
    Miller, K.
    Moisa, C.
    Gradishar, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
    Borner, M.
    Koeberle, D.
    Von Moos, R.
    Saletti, P.
    Rauch, D.
    Hess, V.
    Trojan, A.
    Helbling, D.
    Pestalozzi, B.
    Caspar, C.
    Ruhstaller, T.
    Roth, A.
    Kappeler, A.
    Dietrich, D.
    Lanz, D.
    Mingrone, W.
    ANNALS OF ONCOLOGY, 2008, 19 (07) : 1288 - 1292
  • [35] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [36] Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
    Guo, Weijian
    Zhu, Xiaodong
    Huang, Mingzhu
    Wang, Yusheng
    Chen, Zhiyu
    Feng, Wanjing
    He, Yifu
    Zhang, Xiaowei
    Liu, Xin
    Wang, Chenchen
    Zhang, Wen
    Ying, Jieer
    Wu, Jun
    Yang, Lei
    Qin, Yanru
    Zhao, Xiaoying
    Li, Wenhua
    Zhang, Zhe
    Qiu, Lixin
    Wang, XiaoFeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
    J Feliu
    A Salud
    P Escudero
    L Lopez-Gómez
    M Bolaños
    A Galán
    J-M Vicent
    A Yubero
    F Losa
    J De Castro
    M Á de Mon
    E Casado
    M González-Barón
    British Journal of Cancer, 2006, 94 : 969 - 975
  • [38] XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
    Feliu, J
    Salud, A
    Escudero, P
    Lopez-Gómez, L
    Bolaños, M
    Galán, A
    Vicent, JM
    Yubero, A
    Losa, F
    De Castro, J
    de Mon, MA
    Casado, E
    González-Barón, M
    Oncopaz Cooperative Grp
    BRITISH JOURNAL OF CANCER, 2006, 94 (07) : 969 - 975
  • [39] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [40] Phase II trial of oxaliplatin plus capecitabine as first-line treatment in patients with advanced gastric cancer (AGC)
    Palumbo, R.
    Bernardo, A.
    Strada, M. R.
    Poggi, G.
    Teragni, C.
    Delmonte, A.
    Frascaroli, M.
    Jedrychowska, I
    Canto, A. M.
    Bernardo, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI51 - XI52
12345